Loading
Intraductal papillary mucinous neoplasms are fluid-filled growths in the pancreatic ducts that make mucus and can slowly turn into pancreatic cancer, one of the few chances to catch pancreatic cancer before it starts. Most are watched with scans for years, and surgery is reserved for the ones with warning signs such as a widened main duct, a solid nodule inside the cyst or jaundice.
Intraductal papillary mucinous neoplasm (IPMN) is a mucin-producing epithelial neoplasm growing within the main pancreatic duct, its side branches or both. Main-duct and mixed-type IPMNs carry a substantial risk of high-grade dysplasia or invasive cancer at resection; branch-duct IPMNs, the commonest incidental cyst, progress in only a small minority over years. Mucinous cystic neoplasms (MCNs) occur almost only in women, in the body or tail, and have ovarian-type stroma; serous cystadenomas are benign and linked to VHL; solid pseudopapillary neoplasms are low-grade tumours of young women driven by CTNNB1. IPMNs carry KRAS and GNAS mutations early and acquire TP53, CDKN2A and SMAD4 changes as they progress, and cyst fluid analysis for CEA, glucose and mutations helps tell mucinous from non-mucinous cysts.
Management follows the international Fukuoka and Kyoto (2024) guidelines and the European consensus. High-risk stigmata (obstructive jaundice from a head cyst, an enhancing mural nodule of 5 mm or more, main duct of 10 mm or more, or positive cytology) call for resection in fit patients. Worrisome features (cyst of 3 cm or more, thickened enhancing wall, main duct 5 to 9 mm, smaller nodules, rapid growth, raised CA 19-9, new diabetes, pancreatitis) lead to endoscopic ultrasound with fluid sampling and closer surveillance. Cysts without these features are followed with MRI or endoscopic ultrasound at intervals set by size, and the question of when surveillance can stop in older patients with stable small cysts is unresolved.
Surgery is pancreatoduodenectomy or distal pancreatectomy; invasive cancer arising in an IPMN is staged and treated as pancreatic ductal adenocarcinoma, though colloid-type invasive IPMN carcinomas have a better outcome, and the remaining pancreas needs continued surveillance because IPMN is a field disease. Research aims at cyst fluid and blood biomarkers that separate the cysts that will progress from the many that never will, at artificial intelligence reading of scans, and at the link between new-onset diabetes and early pancreatic cancer.
Pancreatic cysts are found incidentally on scans in a few percent of adults and in a much larger share of people over 70; most are harmless, but intraductal papillary mucinous neoplasms and mucinous cystic neoplasms can progress to pancreatic cancer, and IPMNs are the precursor of a minority of pancreatic cancers.
Most pancreatic cancers arise in the head next to the bile duct, which is why jaundice is the presenting sign; bile duct cancers are named by where along the tree they sit.
Same organ: Glucagonoma, VIPoma, Somatostatinoma, Pancreatic ductal adenocarcinoma, Biliary tract cancer (cholangiocarcinoma), Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma (perihilar and distal), Biliary tract cancer (all types), Neuroendocrine tumours, Pancreatic neuroendocrine tumours, Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma, Gallbladder cancer, Gallbladder adenocarcinoma, Papillary carcinoma of the gallbladder, Mucinous carcinoma of the gallbladder, Adenosquamous and squamous carcinoma of the gallbladder, Neuroendocrine carcinoma of the gallbladder, Incidental gallbladder cancer (found after cholecystectomy), Carcinoma in situ and dysplasia of the gallbladder, Cystic duct carcinoma, Ampullary cancer (ampulla of Vater), Resectable pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Pancreatic acinar cell carcinoma, Pancreatoblastoma, Adenosquamous carcinoma of the pancreas, Colloid (mucinous non-cystic) carcinoma of the pancreas, Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma), Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma), Solid pseudopapillary neoplasm of the pancreas
Background: CA 19-9. Also on OnCo: Symptoms and red flags · Early detection roadmap.
Characterise with MRI and MRCP or pancreas-protocol CT; endoscopic ultrasound with fluid analysis when the cyst type is unclear or worrisome features are present.
Resection (pancreatoduodenectomy or distal pancreatectomy) for obstructive jaundice, an enhancing mural nodule of 5 mm or more, a main duct of 10 mm or more, or positive cytology, in patients fit for surgery.
Endoscopic ultrasound and fluid sampling; resection or short-interval surveillance depending on findings, age and fitness.
MRI or endoscopic ultrasound at intervals set by cyst size, continued while the patient remains a surgical candidate; the remaining pancreas is followed after resection.
Staged and treated as pancreatic ductal adenocarcinoma with resection and adjuvant chemotherapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.
The current international standard for deciding which pancreatic cysts to operate on, which to watch and for how long.
It gives surveillance a target and a timetable: catch high-grade dysplasia and there are about three years before invasion, and TGF-beta pathway loss is the event to detect.
The rulebook behind the CAPS cohorts and the UK EUROPAC programme; it is also the reason surveillance for carriers is not yet a routine NHS service, because the consortium itself asked for it to stay within research until benefit was shown.
A cancer next to a cyst is not necessarily from the cyst, so removing the cyst does not always remove the risk, and surveillance must cover the whole gland.
European centres manage pancreatic cysts by this guideline; its lifelong surveillance stance is the main point of difference from the American and Kyoto guidelines.
Risk stratification of a cyst cannot assume the nearby cancer came from it, and the whole gland stays at risk after cyst resection.
It reframes multifocal high-grade dysplasia found at surveillance: the pancreas may hold one spreading lesion rather than several, which bears on how much gland to remove.
Query for this cancer: (TITLE:"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors" OR ABSTRACT:"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors" OR TITLE:"IPMN" OR ABSTRACT:"IPMN" OR TITLE:"Pancreatic cyst" OR ABSTRACT:"Pancreatic cyst" OR TITLE:"Mucinous cystic neoplasm" OR ABSTRACT:"Mucinous cystic neoplasm" OR TITLE:"MCN" OR ABSTRACT:"MCN" OR TITLE:"Pancreatic cystic neoplasm" OR ABSTRACT:"Pancreatic cystic neoplasm") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Bleeding that does not stop by itself, bleeding from more than one site, or new bruising in several places or one large area.
The three main regimens share low blood counts, tiredness, sickness and sore mouth; FOLFIRINOX and NALIRIFOX add irinotecan diarrhoea and oxaliplatin's cold-triggered tingling and rare throat spasm, gemcitabine with nab-paclitaxel adds hair loss and neuropathy, and every regimen comes with the same temperature rule for ringing the 24-hour line.
See all on the product pages:FOLFIRINOX / mFOLFIRINOX·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.